Company news
Rain Enhancement Technologies Holdco, Inc. news in 2021
Rain Enhancement Technologies Holdco, Inc.'s news releases, calls and decks from 2021, newest first.
Rain Therapeutics Doses First Patient in Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2)
November 18, 2021
Rain Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Progress
November 9, 2021
Rain Therapeutics Initiates Phase 3 MANTRA Clinical Trial of Milademetan for De-differentiated Liposarcoma and Provides Patient Update from Prior Clinical Program
July 19, 2021
Rain Therapeutics Announces Collaboration with Tempus for Genomic Analysis in Planned MDM2-Amplified Phase 2 Basket Trial of RAIN-32
June 2, 2021
Rain Therapeutics Announces Patient Referral Partnership for the Planned MDM2-Amplified Phase 2 Basket Trial of RAIN-32
June 1, 2021
Rain Therapeutics Appoints Robert Doebele, M.D., Ph.D. as President
May 19, 2021